DAUPHINE: a randomized phase II study of danoprevir/ritonavir plus peginterferon alpha-2a/ribavirin in HCV genotypes 1 or 4-Reference-Cited by-同舟云学术

DAUPHINE: a randomized phase II study of danoprevir/ritonavir plus peginterferon alpha-2a/ribavirin in HCV genotypes 1 or 4

Published:2014-02-12 Issue:1 Volume:35 Page:108-119
ISSN:1478-3223
Container-title:Liver International
language:en
Short-container-title:Liver Int

Author:

Everson Gregory¹,Cooper Curtis²,Hézode Christophe³,Shiffman Mitchell L.⁴,Yoshida Eric⁵,Beltran-Jaramillo Teresita⁶,Andreone Pietro⁷,Bruno Savino⁸,Ferenci Peter⁹,Zeuzem Stefan¹⁰,Brunda Michael¹¹,Le Pogam Sophie¹¹,Nájera Isabel¹²,Zhou Julian¹³,Navarro Mercidita T.¹⁴,Voulgari Athina¹⁵,Shulman Nancy S.¹⁴,Yetzer Ellen S.¹⁴

Affiliation:

1. School of Medicine; University of Colorado; Denver CO USA

2. The Ottawa Hospital; University of Ottawa; Ottawa ON Canada

3. Université Paris XII; Hôpital Henri Mondor; Créteil France

4. Bon Secours Health System; Liver Institute of Virginia; Richmond and Newport News VA USA

5. University of British Columbia; Vancouver BC Canada

6. Asesor del departamento de Inmunoanálisis; Médico especialista en Medicina Interna; Mexico Mexico

7. Dipartimento di Scienze Mediche e Chirurgiche; Alma Mater Studiorum; University of Bologna; Bologna Italy

8. Liver Unit; Azienda Ospedaliera Fatebenefratelli e Oftalmico; Milan Italy

9. Medical University of Vienna; Vienna Austria

10. J.W. Goethe University Hospital; Frankfurt Germany

11. Hoffmann-La Roche Inc; Nutley NJ USA